TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3140134

Group type: EXPERIMENTAL
Intervention: Cyclosporin alone (9 subjects)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Cyclosporin and prednisolone (10 subjects)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Azathioprine and prednisolone (9 subjects)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Cyclosporin and prednisolone (6 subjects, measured at 2 years)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Azathioprine and prednisolone (6 subjects, measured at 2 years)
Number of subjects: 28
Study: 1095133

Group type: EXPERIMENTAL
Intervention: Indomethacin 100 mg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Aspirin soluble 4 g/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Indomethacin and aspirin taken together
Number of subjects: 20
Study: 30646167

Group type: EXPERIMENTAL
Intervention: Head CT Choice decision aid
Number of subjects: 971

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 971

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 971
Study: 27401083

Group type: EXPERIMENTAL
Intervention: Propofol anaesthesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sevoflurane anaesthesia
Number of subjects: 60
Study: 24342115

Group type: EXPERIMENTAL
Intervention: Psychotherapy (eight-week body-mind-spirit group psychotherapy)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control (one-session psychoeducation)
Number of subjects: 71
Study: 23341786

Group type: EXPERIMENTAL
Intervention: Definitive chemoradiotherapy (CRT)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Postoperative radiotherapy (SRT)
Number of subjects: 124
Study: 20389106

Group type: EXPERIMENTAL
Intervention: High-fat meal (fat content: 38 g, energy content: 640 kcal)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Low-fat meal (fat content: 2 g, energy content: 320 kcal)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Both meals
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 7
Study: 18480831

Group type: EXPERIMENTAL
Intervention: Central augmentation index (CAI%)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Aortic strain (AoS)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Odds ratio (OR) of AoS for diastolic dysfunction
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Odds ratio (OR) of CAI for diastolic dysfunction
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Addition of CAI to multivariable model
Number of subjects: 143
Study: 16145341

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (LGG) at 10 to 10 cfu/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (unsupplemented formula)
Number of subjects: 0
Study: 14700092

Group type: EXPERIMENTAL
Intervention: Hypermetropic group
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Low myopic group
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Medium myopic group
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: High myopic group
Number of subjects: 131
Study: 10772429

Group type: EXPERIMENTAL
Intervention: Levofloxacin (500 mg qd x 5 d)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 8882668

Group type: EXPERIMENTAL
Intervention: Alveolar macrophages from AIDS patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AIDS patients with Pneumocystis carinii infection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study: 2059758

Group type: EXPERIMENTAL
Intervention: T cell depletion
Number of subjects: 48

Group type: COMPARATOR
Intervention: Cyclosporin and methotrexate (CSA + MTX)
Number of subjects: 48
Study: 6851564

Group type: EXPERIMENTAL
Intervention: ONO 802 pessaries (1 mg of 16, 16-dimethyl-trans-delta 2-prostaglandin E1 methyl ester)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo pessaries (no treatment)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: ONO 802 pessaries
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo pessaries
Number of subjects: 195
Study: 30144521

Group type: EXPERIMENTAL
Intervention: High-Dose Accelerated (HDA) Vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Dose (SD) Vaccination
Number of subjects: 0
Study: 28229275

Group type: EXPERIMENTAL
Intervention: Active Treatment Group (hyaluronic acid-based vaginal moisturizer)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Active Treatment Group (prebiotic vaginal moisturizer)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Active Group-H
Number of subjects: 57

Group type: COMPARATOR
Intervention: Usual Care Group
Number of subjects: 57
Study: 24754682

Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 30
Study: 22417647

Group type: EXPERIMENTAL
Intervention: Self-performed joint counts by patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-performed joint counts in patients in remission (SDAI ≤ 3.3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Separate training session for patients
Number of subjects: 0
Study: 20962623

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day (started 3 days before coronary angiography)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Chronic statin therapy
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 240
Study: 17396251

Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg/day for 14 days (group A1)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg/day for 14 days (group A2)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group (B1 and B2) receiving only pain-relieving therapy
Number of subjects: 113
Study: 16223069

Group type: EXPERIMENTAL
Intervention: Moderate intensity comprehensive behavioral treatment based on motivational interviewing and Cognitive Behavioral Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standardized abstinence-oriented treatment
Number of subjects: 0
Study: 12150228

Group type: EXPERIMENTAL
Intervention: Just deserts perspective
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: Deterrence perspective
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: Proposed model confirmed through structural equation modeling (SEM)
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: Individual sentencing decisions
Number of subjects: 1016
Study: 9702644

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone therapy (0.2 U/kg subcutaneously daily for 28 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7617248

Group type: EXPERIMENTAL
Intervention: Cefotetan (average daily dose of 4 g in half of the cases and 6 g in the others, average treatment period of 8 days)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Cefotetan
Number of subjects: 25
Study: 3567124

Group type: EXPERIMENTAL
Intervention: Meptazinol (1.5 mg/kg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Pethidine (1.5 mg/kg)
Number of subjects: 32
Study: 29203068

Group type: EXPERIMENTAL
Intervention: 2-minute riboflavin dosing interval
Number of subjects: 510

Group type: COMPARATOR
Intervention: 5-minute riboflavin dosing interval
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Both dosing intervals
Number of subjects: 510
Study: 27483127

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 11
Study: 25196117

Group type: EXPERIMENTAL
Intervention: Continued glucocorticoid use
Number of subjects: 2485

Group type: COMPARATOR
Intervention: Glucocorticoid withdrawal
Number of subjects: 2485
Study: 22695185

Group type: EXPERIMENTAL
Intervention: EGb-761 (Ginkgo biloba) 240 mg per day for 12 weeks
Number of subjects: 368

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 368
Study: 20521321

Group type: EXPERIMENTAL
Intervention: water plus 75 mg of caffeine and 75 g of glucose
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: water plus 75 mg of caffeine
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: water plus 75 g of glucose
Number of subjects: 72

Group type: COMPARATOR
Intervention: water (150 ml)
Number of subjects: 72
Study: 18954244

Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Videophone follow-up
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All interventions (telephone, videophone, usual care)
Number of subjects: 0
Study: 19826418

Group type: EXPERIMENTAL
Intervention: mFOLFIRI.3
Number of subjects: 61

Group type: COMPARATOR
Intervention: mFOLFOX
Number of subjects: 61
Study: 15761605

Group type: EXPERIMENTAL
Intervention: Ivermectin (300 microg/kg body weight at a single dose, repeated after 24 h)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 11726264

Group type: EXPERIMENTAL
Intervention: Subject A (male weight-trained, age 21)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (18 similarly trained men, age 24.7)
Number of subjects: 19
Study: 9239586

Group type: EXPERIMENTAL
Intervention: Propofol Patient-Controlled Sedation (PCS) - 0.5 mg/kg, lockout interval 3 min
Number of subjects: 19

Group type: COMPARATOR
Intervention: Anesthesiologist-administered midazolam-fentanyl sedation
Number of subjects: 19
Study: 8307806

Group type: EXPERIMENTAL
Intervention: Geriatric assessment team (n = 33)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard care (nonteam, n = 36)
Number of subjects: 69
Study: 3326677

Group type: EXPERIMENTAL
Intervention: Meclofenamate sodium 200 mg
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Meclofenamate sodium 100 mg
Number of subjects: 327

Group type: COMPARATOR
Intervention: Codeine 60 mg
Number of subjects: 327

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 327
Study: 11421505

Group type: EXPERIMENTAL
Intervention: Metered dose inhaler (MDI) with terbutaline 1.5 mg (six puffs) and ipratropium 120 microg (six puffs) via two inspirations to total lung capacity and a 10-sec breath-hold per puff
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Metered dose inhaler (MDI) with terbutaline 1.5 mg (six puffs) and ipratropium 120 microg (six puffs) via six tidal breaths
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nebulized terbutaline 5 mg and ipratropium 500 microg
Number of subjects: 20
Study: 31294598

Group type: EXPERIMENTAL
Intervention: Conjoint behavioral consultation (CBC) intervention
Number of subjects: 267

Group type: COMPARATOR
Intervention: Control group (business as usual)
Number of subjects: 267
Study: 30132426

Group type: EXPERIMENTAL
Intervention: SAM treatment plus flocculent/disinfectant water treatment
Number of subjects: 901

Group type: EXPERIMENTAL
Intervention: SAM treatment plus chlorine disinfectant
Number of subjects: 901

Group type: EXPERIMENTAL
Intervention: SAM treatment plus ceramic water filter
Number of subjects: 901

Group type: COMPARATOR
Intervention: Standard SAM treatment
Number of subjects: 901
Study: 27459527

Group type: EXPERIMENTAL
Intervention: Levothyroxine (Group A)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Untreated euthyroid thyroid antibody positive women (Group B)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Untreated thyroid antibody negative women (Group C)
Number of subjects: 198
Study: 25224315

Group type: EXPERIMENTAL
Intervention: Communication Quality Assurance intervention (report card)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (no report card)
Number of subjects: 92
Study: 22617015

Group type: EXPERIMENTAL
Intervention: Mesalazine granules 1.5 g once-daily
Number of subjects: 487

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 487
Study: 20429742

Group type: EXPERIMENTAL
Intervention: Corset treatment (A)
Number of subjects: 91

Group type: COMPARATOR
Intervention: No corset treatment (B)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Very low calorie diet (VLCD)
Number of subjects: 91
Study: 17267922

Group type: EXPERIMENTAL
Intervention: Drugs approved by the EMEA for psychiatric disorders
Number of subjects: 0
Study: 15177518

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 12095067

Group type: EXPERIMENTAL
Intervention: 5‐aminolevulinic acid (ALA) with photodynamic therapy (PDT)
Number of subjects: 0
Study: 9828754

Group type: EXPERIMENTAL
Intervention: Nutrition education intervention programme
Number of subjects: 104
Study: 7863823

Group type: EXPERIMENTAL
Intervention: Short-term rhGH treatment (1 week)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sustained rhGH treatment (5 weeks)
Number of subjects: 8
Study: 2692402

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 30974993

Group type: EXPERIMENTAL
Intervention: Turbinator wand
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Reflex Ultra wand
Number of subjects: 150
Study: 28007634

Group type: EXPERIMENTAL
Intervention: Multi-component intervention including culturally tailored interactive multimedia component and counseling sessions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study: 25201887

Group type: EXPERIMENTAL
Intervention: Low-dose fish oil (3 capsules/day, 1080 mg eicosapentaenoic acid + docosahexaenoic acid)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Low-dose fish oil
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-dose fish oil
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (corn oil, linoleic acid)
Number of subjects: 24
Study: 23375618

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 589

Group type: COMPARATOR
Intervention: Carvedilol
Number of subjects: 589
Study: 22012640

Group type: EXPERIMENTAL
Intervention: vMLSS (13.56±0.90 km·h‐1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: v5×2000 (12.93±0.90 km·h‐1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Tlim at vMLSS (64±15 min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Tlim at v5×2000 (94±21 min)
Number of subjects: 8
Study: 17362279

Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride 25 mg taken 1-2 hours before sexual activity for 8 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo taken 1-2 hours before sexual activity for 8 weeks
Number of subjects: 60
Study: 17062648

Group type: EXPERIMENTAL
Intervention: Rituximab + methotrexate
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo + methotrexate
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Rituximab alone
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Rituximab + cyclophosphamide
Number of subjects: 161
Study: 12855215

Group type: EXPERIMENTAL
Intervention: Health educator-led classroom program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-instruction classroom program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 0
Study: 10493673

Group type: EXPERIMENTAL
Intervention: Circulating thrombopoietin (TPO) concentrations in SSc
Number of subjects: 13

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Patients with rheumatoid arthritis (RA)
Number of subjects: 13
Study: 8757423

Group type: EXPERIMENTAL
Intervention: Nystatin pastilles (200,000 U)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo pastilles
Number of subjects: 128
Study: 1683811

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 7075121

Group type: EXPERIMENTAL
Intervention: 250 mg of naproxen daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 750 mg of naproxen daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1500 mg of naproxen daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Naproxen (all doses)
Number of subjects: 24
Study: 31582358

Group type: EXPERIMENTAL
Intervention: hIVIG (0.25 g/kg bodyweight, 500 mL infusion)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: hIVIG
Number of subjects: 308

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study: 26280216

Group type: EXPERIMENTAL
Intervention: Postural change from head up tilt (HUT) to supine position
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 30° passive leg raising (PLR)
Number of subjects: 15
Study: 24019197

Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol fumarate (MF/F) with spacer (AeroChamber Plus® with Flow‐Vu® Anti‐Static Valved Holding Chamber)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol fumarate (MF/F) without spacer
Number of subjects: 87

Group type: COMPARATOR
Intervention: Mometasone furoate/formoterol fumarate (MF/F) with spacer
Number of subjects: 87

Group type: COMPARATOR
Intervention: F-Dry Powder Inhaler (F-DPI)
Number of subjects: 87
Study: 23058047

Group type: EXPERIMENTAL
Intervention: Halofantrine (HF) 24 mg/kg (8 mg/kg every 6 h for 24 h)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Halofantrine (HF) 72 mg/kg (8 mg/kg every 6 to 10 h for 3 days)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Bayesian analysis of patient data
Number of subjects: 194

Group type: COMPARATOR
Intervention: Healthy volunteers (HF doses of 250, 500, and 1000 mg)
Number of subjects: 194
Study: 19589010

Group type: EXPERIMENTAL
Intervention: Letter or call
Number of subjects: 13057

Group type: EXPERIMENTAL
Intervention: Letter-call or call-letter
Number of subjects: 13057

Group type: EXPERIMENTAL
Intervention: Letter-call-letter
Number of subjects: 13057

Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 13057
Study: 17301574

Group type: EXPERIMENTAL
Intervention: NYVAC expressing clade C gp120
Number of subjects: 0
Study: 15247731

Group type: EXPERIMENTAL
Intervention: Conventional large bore nephrostomy drainage (20Fr)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Small bore nephrostomy drainage (9Fr)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No nephrostomy drainage (tubeless)
Number of subjects: 30
Study: 12539424

Group type: EXPERIMENTAL
Intervention: Self-made denture adhesive paste
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fixodent denture adhesive paste
Number of subjects: 24
Study: 10193451

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other beta-blockers
Number of subjects: 0
Study: 7713273

Group type: EXPERIMENTAL
Intervention: Type 1 Diabetes
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Type 2 Diabetes
Number of subjects: 120
Study: 3234673

Group type: EXPERIMENTAL
Intervention: Vasopressin (VS) IM 0.3 U/kg
Number of subjects: 34
Study: 30568005

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Combined AE and DASH diet
Number of subjects: 160

Group type: COMPARATOR
Intervention: DASH diet
Number of subjects: 160

Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Greater aerobic fitness
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Reduced CVD risk
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Reduced sodium intake
Number of subjects: 160
Study: 28902127

Group type: EXPERIMENTAL
Intervention: Exercise therapy (forced treadmill exercise)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-exercise group (control)
Number of subjects: 0
Study: 25979318

Group type: EXPERIMENTAL
Intervention: Exercise training (aerobic and resistance training)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Healthy living control arm
Number of subjects: 116
Study: 23708326

Group type: EXPERIMENTAL
Intervention: BCAA granules (Livact, 12 g/day) for 60 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BCAA treatment
Number of subjects: 0
Study: 20684955

Group type: EXPERIMENTAL
Intervention: Metformin 850 mg two times per day
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg daily
Number of subjects: 43

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 43

Group type: COMPARATOR
Intervention: Healthy age‐ and body mass index‐matched women (control group)
Number of subjects: 43
Study: 19212906

Group type: EXPERIMENTAL
Intervention: Sodium ferrigluconate complex (SFGC)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Iron-sucrose (IS)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Low molecular weight iron dextran (ID)
Number of subjects: 59
Study: 17093110

Group type: EXPERIMENTAL
Intervention: Presurvey letter
Number of subjects: 0
Study: 15001611

Group type: EXPERIMENTAL
Intervention: Phytoestrogens (114 mg of isoflavonoids)
Number of subjects: 55
Study: 11337211

Group type: EXPERIMENTAL
Intervention: Systemic infection (properly completed reports)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: High psychological stress (properly completed reports)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Systemic infection (improperly completed reports)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: High psychological stress (improperly completed reports)
Number of subjects: 308
Study: 9041098

Group type: EXPERIMENTAL
Intervention: Conjugated estrogen (0.625 mg per day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Conjugated estrogen + medroxyprogesterone acetate (2.5 mg daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Transdermal estradiol (0.1 mg per day)
Number of subjects: 50
Study: 8327423

Group type: EXPERIMENTAL
Intervention: High-voltage pulsed galvanic stimulation (75 V, 10 Hz) applied to the back at spinal level T6
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 3559814

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 2562269

Group type: EXPERIMENTAL
Intervention: Dentifrice containing 1% sodium polyphosphate
Number of subjects: 148

Group type: COMPARATOR
Intervention: Dentifrice A containing 5% sodium pyrophosphate
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 148
Study: 31984661

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg once daily (n=213)
Number of subjects: 422

Group type: COMPARATOR
Intervention: Placebo (n=209)
Number of subjects: 422